Federica Longo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Federica Longo has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Gattuso
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
2 shared publications - Luca Falzone
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
2 shared publications - Massimo Libra
Department of Biomedical and Biotechnological Sciences, Oncologic, Clinical and General Pathology Section, University of Catania, 95124 Catania, Italy
2 shared publications - Alessandro Lavoro
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
1 shared publication - Ammara Khalid
Department of Biotechnology, University of Sialkot, Sialkot, Pakistan
1 shared publication - Antonio Di Cataldo
Department of Medical and Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania, 95123 Catania, Italy
1 shared publication
Latest Publications
- 21 July 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (8) , 1-23
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies
The disruption of the epigenetic patterns and its impact on gene expression is recognized as a critical factor in the initiation and progression of cancer. Altered patterns of DNA methylation, histone modifications, and non-coding RNA expression are distinctive features of tumorigenesis. These dynamic shifts in the epigenetic landscape during oncogenic transformation are intricately linked to tumor heterogeneity, the sustained capacity for self-renewal, and the ability to undergo multi-lineage differentiation. The abnormal reprogramming of cancer stem cells presents a formidable challenge in cancer treatment and drug resistance. However, the reversible nature of epigenetic modifications holds significant potential for developing novel cancer treatments through the targeted inhibition of epigenetic modifiers. Utilizing this approach as a standalone therapy or combined with other anticancer treatments has yielded promising outcomes. In this review, we emphasize the central role of epigenetic dysregulation in cancer pathogenesis, epigenetic changes in the cancer genome, and the latest advancements in cancer therapy, particularly the potential of epigenetic factors as biomarkers for early detection and their application in current cancer treatment modalities.
- 21 July 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (8) , 1-23
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies
The disruption of the epigenetic patterns and its impact on gene expression is recognized as a critical factor in the initiation and progression of cancer. Altered patterns of DNA methylation, histone modifications, and non-coding RNA expression are distinctive features of tumorigenesis. These dynamic shifts in the epigenetic landscape during oncogenic transformation are intricately linked to tumor heterogeneity, the sustained capacity for self-renewal, and the ability to undergo multi-lineage differentiation. The abnormal reprogramming of cancer stem cells presents a formidable challenge in cancer treatment and drug resistance. However, the reversible nature of epigenetic modifications holds significant potential for developing novel cancer treatments through the targeted inhibition of epigenetic modifiers. Utilizing this approach as a standalone therapy or combined with other anticancer treatments has yielded promising outcomes. In this review, we emphasize the central role of epigenetic dysregulation in cancer pathogenesis, epigenetic changes in the cancer genome, and the latest advancements in cancer therapy, particularly the potential of epigenetic factors as biomarkers for early detection and their application in current cancer treatment modalities.
- Open Access
- 30 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1219
Diagnostic and Prognostic Significance of a Four-miRNA Signature in Colorectal Cancer
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and one of the leading causes of cancer death worldwide. Despite diagnostic and therapeutic advances, CRC mortality remains high, especially in industrialized countries. Numerous studies have highlighted the pathogenetic role of altered microRNA (miRNA) expression among the various factors contributing to the development and progression of colorectal cancer (CRC). However, the data regarding specific miRNAs involved in CRC pathogenesis remain inconsistent, and no miRNAs have been recognized so far as reliable or effective biomarkers for the diagnosis of this tumor type. To identify novel miRNA biomarkers in CRC, this study validated the expression levels of a four-miRNA signature predicted to be involved in CRC by analyzing both tissue and liquid biopsy samples. Our experimental and bioinformatics results highlighted the diagnostic potential of hsa-miR-21-5p, hsa-miR-503-5p, and hsa-miR-375, as well as the potential prognostic value of hsa-miR-497-5p overexpression and hsa-miR-375-3p downregulation. Overall, the results obtained suggest the diagnostic and prognostic significance of this four-miRNA signature in CRC.
- 30 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1219
Open AccessDiagnostic and Prognostic Significance of a Four-miRNA Signature in Colorectal Cancer
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and one of the leading causes of cancer death worldwide. Despite diagnostic and therapeutic advances, CRC mortality remains high, especially in industrialized countries. Numerous studies have highlighted the pathogenetic role of altered microRNA (miRNA) expression among the various factors contributing to the development and progression of colorectal cancer (CRC). However, the data regarding specific miRNAs involved in CRC pathogenesis remain inconsistent, and no miRNAs have been recognized so far as reliable or effective biomarkers for the diagnosis of this tumor type. To identify novel miRNA biomarkers in CRC, this study validated the expression levels of a four-miRNA signature predicted to be involved in CRC by analyzing both tissue and liquid biopsy samples. Our experimental and bioinformatics results highlighted the diagnostic potential of hsa-miR-21-5p, hsa-miR-503-5p, and hsa-miR-375, as well as the potential prognostic value of hsa-miR-497-5p overexpression and hsa-miR-375-3p downregulation. Overall, the results obtained suggest the diagnostic and prognostic significance of this four-miRNA signature in CRC.
- Open Access
- 31 October 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (11) , 1083
Intratumoral Microbiota: Insights from Anatomical, Molecular, and Clinical Perspectives
The human microbiota represents a heterogeneous microbial community composed of several commensal, symbiotic, and even pathogenic microorganisms colonizing both the external and internal body surfaces. Despite the term “microbiota” being commonly used to identify microorganisms inhabiting the gut, several pieces of evidence suggest the presence of different microbiota physiologically colonizing other organs. In this context, several studies have also confirmed that microbes are integral components of tumor tissue in different types of cancer, constituting the so-called “intratumoral microbiota”. The intratumoral microbiota is closely related to the occurrence and development of cancer as well as to the efficacy of anticancer treatments. Indeed, intratumoral microbiota can contribute to carcinogenesis and metastasis formation as some microbes can directly cause DNA damage, while others can induce the activation of proinflammatory responses or oncogenic pathways and alter the tumor microenvironment (TME). All these characteristics make the intratumoral microbiota an interesting topic to investigate for both diagnostic and prognostic purposes in order to improve the management of cancer patients. This review aims to gather the most recent data on the role of the intratumoral microbiota in cancer development, progression, and response to treatment, as well as its potential diagnostic and prognostic value.
- 31 October 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (11) , 1083
Open AccessIntratumoral Microbiota: Insights from Anatomical, Molecular, and Clinical Perspectives
The human microbiota represents a heterogeneous microbial community composed of several commensal, symbiotic, and even pathogenic microorganisms colonizing both the external and internal body surfaces. Despite the term “microbiota” being commonly used to identify microorganisms inhabiting the gut, several pieces of evidence suggest the presence of different microbiota physiologically colonizing other organs. In this context, several studies have also confirmed that microbes are integral components of tumor tissue in different types of cancer, constituting the so-called “intratumoral microbiota”. The intratumoral microbiota is closely related to the occurrence and development of cancer as well as to the efficacy of anticancer treatments. Indeed, intratumoral microbiota can contribute to carcinogenesis and metastasis formation as some microbes can directly cause DNA damage, while others can induce the activation of proinflammatory responses or oncogenic pathways and alter the tumor microenvironment (TME). All these characteristics make the intratumoral microbiota an interesting topic to investigate for both diagnostic and prognostic purposes in order to improve the management of cancer patients. This review aims to gather the most recent data on the role of the intratumoral microbiota in cancer development, progression, and response to treatment, as well as its potential diagnostic and prognostic value.